



# Guidelines for the preparation of a contract research organization master file Bangladesh

Directorate General of Drug Administration  
Ministry of Health and Family Welfare  
Govt. of the People's Republic of Bangladesh

Mostly adapted from the © World Health Organization  
WHO Technical Report Series, No. 957, 2010



DIRECTORATE GENERAL OF DRUG  
ADMINISTRATION (DGDA)  
MINISTRY OF HEALTH AND FAMILY WELFARE,  
BANGLADESH



**CONTROLLED COPY**

Issued by:

Issue date: ৮-৭-১৪



## APPROVAL DETAILS

Guideline no: NRA-ET-GI-002

PREPARED BY			
Name	Designation	Signature	Date
Dr. Aysha siddiqua	Pharmacologist	<i>Aysha</i>	26.10.17

CHECKED BY			
Name	Designation	Signature	Date
Md. Salahuddin	Asstt. Director	<i>Md. Salahuddin</i>	26.10.17

APPROVED BY			
Name	Designation	Signature	Date
Dr. Khandaker Sagir Ahmed	Deputy Director	<i>Sagir Ahmed</i>	26.10.17

AUTHORIZED BY			
Name	Designation	Signature	Date
Major General Md .Mustafizur Rahman	Director General	<i>M. Mustafizur Rahman</i>	26.10.17



DIRECTORATE GENERAL OF DRUG  
ADMINISTRATION (DGDA)  
MINISTRY OF HEALTH AND FAMILY WELFARE,  
BANGLADESH



**CONTROLLED COPY**

Issued by:

*[Signature]*

Issue date: 5-7-18

## Contents

1. Background
2. General information
3. Quality management system of the contract research organization
4. Personnel
5. Ethics committee
6. Computer systems
7. Equipment and instruments
8. Documentation
9. Safety monitoring
10. Investigational medicinal products and comparator products
11. Pathology
12. Bioanalytical laboratory
13. Biostatistics
14. Study volunteers
15. Other information



DIRECTORATE GENERAL OF DRUG  
ADMINISTRATION (DGDA)  
MINISTRY OF HEALTH AND FAMILY WELFARE,  
BANGLADESH



**CONTROLLED COPY**

Issued by:

Issue date:

5-7-18



## 1. Background

A contract research organization master file (CROMF) is a document prepared by the contract research organization (CRO) containing specific and factual information about the CRO and the conduct of clinical studies as well as the analyses of samples and related operations (including clinical trials, clinical data management, pharmacokinetics and statistical analysis and regulatory affairs) carried out at the named site. If only some of the operations referred to below are carried out at the site, the master file (MF) needs to be presented only for those operations.

In a case where a CRO is responsible for activities pertaining only to bio analytical procedures, then only sections in the CROMF relating to these should be described. Other sections may be marked as "not applicable".

Where a CRO performs various activities, separate sections could be prepared for the different units, e.g. clinical pharmacology unit (CPU) and bio analytical laboratory (BAL).

A CROMF provides information on the policies, approach and general activities of a CRO. It is not trial-specific as trial-specific data are submitted in a product dossier. It serves as general information to regulators and can be used during preparation for inspections by regulatory inspectors in addition to the trial-specific data and information submitted for assessment. It also provides an overview of the organization's approach to good clinical practices (GCP), good laboratory practices (GLP) and other guidelines pertaining to its activities.

A CROMF should be submitted to the national medicines regulatory authority (NMRA) where such a document is requested. It should be succinct and as far as possible not exceed 25 A4 pages (where appropriate, supportive documentation may be appended).

An updated CROMF should be submitted when requested by the NMRA, or if significant changes have been implemented by the CRO.

## 2. General information

- 2.1 Name and exact address of the CRO, including telephone, fax, 24-hour telephone numbers and e-mail address
- 2.2 Short description of the CRO (including size, location, number of beds, layout and plan, areas for handling samples and waste)
- 2.3 Activities as licensed/authorized by the national authority
- 2.4 Inspections and approvals
  - 2.4.1 Inspections/approvals/accreditations by any regulatory agency
  - 2.4.2 Audits of subcontractors
- 2.5 Type of studies (and indications, where appropriate) performed on site (a list of projects conducted at this site may be provided)
- 2.6 Provisions for insurance
  - 2.6.1 Number of employees engaged in studies, quality storage and distribution
- 2.7 Contract services employed
  - 2.7.1 Use of outside scientific, analytical or other technical assistance in relation to studies and analysis (e.g. clinical laboratory, bio analytical laboratory, X-ray facilities and caterers)
  - 2.7.2 Services outsourced, e.g. contracts with tertiary care hospital for handling of medical emergencies, ambulance facility, nutrition, biomedical waste, chemical waste, caterers, pest control and pathology laboratory



DIRECTORATE GENERAL OF DRUG  
ADMINISTRATION (DGDA)  
MINISTRY OF HEALTH AND FAMILY WELFARE  
BANGLADESH



**CONTROLLED COPY**

Issued by: 

Issue date: 5-7-18

## 3. Quality management system of the contract research organization

## 4. Personnel

(A brief description can be presented in tabular format)

- 4.1 Qualifications, experience and responsibilities of key personnel as applicable
  - 4.1.1 project manager
  - 4.1.2 principal investigator
  - 4.1.3 analytical investigator
  - 4.1.4 biostatistician
  - 4.1.5 clinical research associates
  - 4.1.6 data manager
  - 4.1.7 monitor
  - 4.1.8 the study director(s)
  - 4.1.9 person responsible for quality assurance
- 4.2 Training of personnel:
  - 4.2.1 training policy and procedure (brief description)
  - 4.2.2 training records

## 5. Ethics committee

- 5.1 Constitution and relation to CRO
- 5.2 Procedures including review and approval of protocols

## 6. Computer systems

(Short description)

- 6.1 Hardware
- 6.2 Software (and version number) used (e.g. in the bioanalytical laboratory, in pharmacokinetic and statistical analysis) and change control procedure
- 6.3 Data management systems (include a procedural flow chart and a brief description of query generation and resolution)
- 6.4 Security procedures
- 6.5 Electronic exchange of confidential information
- 6.6 Brief description of validation programme
- 6.7 Back-up and storage of electronic data

## 7. Equipment and instruments

- 7.1 Brief description of major equipment and instruments (a list of equipment is not required)
- 7.2 Qualification, maintenance and calibration program, including the temperature recording systems



**CONTROLLED COPY**

Issued by:

Issue date: 5-7-18



## 8. Documentation

- 8.1 Briefly describe document management systems
- 8.2 Project work flow including quality assurance and control process
- 8.3 Preparation of protocols
- 8.4 Preparation of informed consent forms and subject information forms
- 8.5 Preparation of report forms
- 8.6 Preparation of final report

## 9. Safety monitoring

(Brief description)

Adverse drug reaction reporting procedure

Provisions made for emergencies, including protocols and equipment available

## 10. Investigational medicinal products and comparator products

(Brief description)

- 10.1 Acquisition, storage, handling, sampling and disposal
- 10.2 Pharmacy and dispensing

## 11. Pathology

- 11.1 Biological sample collection and storage
- 11.2 Handling and analysis of biological samples

## 12. Bioanalytical laboratory

(Brief description)

- 12.1 Method development and validation
- 12.2 Reference standard materials used for preparation of calibration standards and quality control samples
- 12.3 Biological matrix storage, and handling of matrix samples
- 12.4 Analysis of unknown samples



DIRECTORATE GENERAL OF DRUG  
ADMINISTRATION (DGDA)  
MINISTRY OF HEALTH AND FAMILY WELFARE,  
BANGLADESH



**CONTROLLED COPY**

Issued by:

Issue date: 5-7-18

- 12.5 Preparation and labeling of reagents
- 12.6 Storage of samples
- 12.7 Stability procedures
- 12.8 Waste management

### **13. Biostatistics**

- 13.1 Data processing and analysis
- 13.2 Data management

### **14. Study volunteers**

- 14.1 Procedure for recruitment
- 14.2 Collecting information on volunteers (e.g. databank), while confidentiality is maintained
- 14.3 Procedure for obtaining informed consent

### **15. Other information**

- 15.1 Power supply system — uninterrupted power supply and generator availability and capacity
- 15.2 Brief description of any other activities performed on site by the CRO
- 15.3 Any other information which the CRO may feel it appropriate to add



DIRECTORATE GENERAL OF DRUG  
ADMINISTRATION (DGDA)  
MINISTRY OF HEALTH AND FAMILY WELFARE,  
BANGLADESH



**CONTROLLED COPY**

Issued by:

Issue date:

5-7-18